AUTOLUS THERAPEUTICS PLC - AMERICAN DEPOSITARY SHA

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

09 ديسمبر 2024 19:30:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

02 ديسمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

12 نوفمبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

08 نوفمبر 2024 16:23:24 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

05 نوفمبر 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

28 أكتوبر 2024 17:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

16 أكتوبر 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

19 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

27 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

08 أغسطس 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

26 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

14 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

31 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

17 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

14 مايو 2024 10:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call

13 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

24 أبريل 2024 10:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

23 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)

02 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Autolus Therapeutics Announces Changes to its Board of Directors

01 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire